Fine-tuning TCAD parameters with real-world feedback from test wafers is essential for quantitatively accurate and predictive results.

Bringing a single drug to market can take more than a decade and cost billions of dollars, with fewer than one in ten candidates successfully reaching approval. Against this backdrop, generative AI is ...

The company offers integrated, technology-driven solutions for fragmented inventory. This helps companies manage expanding ...

Artificial intelligence is fundamentally changing how software is built. It is moving beyond just speeding up tasks. AI is ...

By Lorna Patrick, Chief Operating Officer, Upperton In the world of outsourced drug development and manufacturing, risk ...

The Digital 2026 Global Overview Report shows customers aren’t following your map anymore — they’re building their own across ...

A study published in Engineering delves into the design of sixth-generation (6G) space-air-ground integrated networks (SAGINs) tailored for unmanned ...

Base Case Outlines M&I Resources of 1.83 Billion tonnes at 0.27% Cu and Inferred Resources of 0.24 Billion tonnes at 0.41% Cu 2026 Drill ...

The multiple condition (MC)-retention model is an uncertainty-aware graph-based neural network that predicts liquid chromatography (LC) retention times across multiple column chem ...

Beyond Cutting, a Leap in Productivity The true capability of a high-performance beam saw lies in its ability to marry brute speed with digital intelligence. UNISUNX has focused its engineering ...

As the AI era becomes increasingly shaped by foundation models, the pharmaceutical industry is entering a new phase of opportunity for discovery, design, and decision-making driven by AI for science.

The old measurements of leverage, utilization, margin, billing rate, and realization fall short of the new reality.